Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yaron Rotman

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 19, 2015
Comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32]Yaron Rotman
Pharmacological Research|August 31, 2015
Similarity between studies of dihydromyricetin and reservatrol for NAFLDYaron Rotman
Hepatology (Baltimore, Md.)|June 25, 2017
ReplyVarun Takyar, Yaron Rotman
Gut|May 5, 2017
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' responseYaron Rotman, Arun J Sanyal
The American Journal of Gastroenterology|December 12, 2025
Poor Sensitivity of the Fatty Liver Index Among Lean IndividualsMohammed Rifat Shaik, Yaron Rotman
Gut|September 21, 2016
Current and upcoming pharmacotherapy for non-alcoholic fatty liver diseaseYaron Rotman, Arun J Sanyal
Journal of Virology|May 8, 2009
Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomesYaron Rotman, T Jake Liang
The American Journal of Gastroenterology|January 31, 2023
Nutrition Literacy Is Not Sufficient to Induce Needed Dietary Changes in Nonalcoholic Fatty Liver DiseaseAllison M Carroll, Yaron Rotman
Gut|March 10, 2017
What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liverPhilip M Brown, Yaron Rotman
Hepatology (Baltimore, Md.)|February 3, 2017
Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culpritYaron Rotman, Brent A Neuschwander-Tetri
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 19, 2015
Comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32]Yaron Rotman
Pharmacological Research|August 31, 2015
Similarity between studies of dihydromyricetin and reservatrol for NAFLDYaron Rotman
Hepatology (Baltimore, Md.)|June 25, 2017
ReplyVarun Takyar, Yaron Rotman
Gut|May 5, 2017
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' responseYaron Rotman, Arun J Sanyal
The American Journal of Gastroenterology|December 12, 2025
Poor Sensitivity of the Fatty Liver Index Among Lean IndividualsMohammed Rifat Shaik, Yaron Rotman
Gut|September 21, 2016
Current and upcoming pharmacotherapy for non-alcoholic fatty liver diseaseYaron Rotman, Arun J Sanyal
Journal of Virology|May 8, 2009
Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomesYaron Rotman, T Jake Liang
The American Journal of Gastroenterology|January 31, 2023
Nutrition Literacy Is Not Sufficient to Induce Needed Dietary Changes in Nonalcoholic Fatty Liver DiseaseAllison M Carroll, Yaron Rotman
Gut|March 10, 2017
What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liverPhilip M Brown, Yaron Rotman
Hepatology (Baltimore, Md.)|February 3, 2017
Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culpritYaron Rotman, Brent A Neuschwander-Tetri
Pageof 8